Gangrene Treatment Market Market Trends

Growth Drivers

• An increase in government healthcare expenditure: The aspect of an increase in Medicare and Medicaid services has effectively reflected the surging need, owing to the incidence of diabetes and an increase in the elderly population globally, which has positively impacted the market across different nations. Besides, as per an article published by Rare Diseases India in December 2024, the regional government established the National Fund for Rare Diseases (NFRD), with the provision of ₹974 crore (USD 110 million) for the financial year of 2024 and 2025. Therefore, with an increase in chronic conditions, the government has come forward to ensure federal spending, thus suitable for the market’s upliftment.
• Enhanced patient pool with chronic diseases: These conditions effectively demand continuous medical attention as they tend to limit activities of daily living, which is also proliferating the market. As per the October 2024 CDC data report, chronic conditions cater to USD 4.9 trillion in yearly healthcare care expenses. Besides, 6 in 10 people from America are affected with almost one chronic disease, and 4 in 10 have more than two chronic diseases. This growing patient pool continues to bolster the market for early diagnosis, wound management products, and advanced surgical treatments requirements.
• Chemical advancements in wound care: The creation and incorporation of antimicrobial dressings, foam dressings, hydrocolloids, and bio-engineered skin substitutes leads to improving healing rates and combat infection risk, which is also uplifting the global market. According to the May 2022 NLM article, epithelial keratins comprise 1% of sulfur, along with 3% of cysteine, suitable for stabilizing cells in epithelia. Besides, trichocyte keratins constitute 5% of sulfur, along with 4% to 17% of cysteine, thus also suitable for healing wounds. Therefore, the presence of these chemicals is a huge growth factor for the overall market across different nations.

Antimicrobial Resistance (AMR) Driving the Market

Source: World Health Organization (WHO)

Challenges

• Pricing restrictions and caps in government healthcare: Several countries have robust price caps on the advanced treatments for gangrene. This high cost is within their government-funded healthcare systems. For instance, in 2023, a company collaborated with a health authority in Germany to overcome these challenges in pricing, hence boosting the market access by 10.2%. Apart from these, reimbursement challenges often restrict the use of high-cost advanced biologic dressings by 20.2% among hospital patients.